基于DCE-MRI的影像组学预测乳腺癌新辅助治疗反应
回顾性纳入142例原发浸润性乳腺癌患者,于新辅助治疗前及两周期后行DCE-MRI,按7:3随机分为训练组与测试组,构建基于治疗前、早期治疗及变化影像组学特征、直径相对退缩率(Diameter%)和临床指标的模型。测试集中变化影像组学模型AUC为0.87,融合模型预测病理完全缓解的AUC在训练集和测试集均为0.91,优于Diameter%模型(P=0和0.039)。
要点
- 基于新辅助治疗前及早期治疗DCE-MRI的变化影像组学模型在测试集预测pCR的AUC为0.87,高于治疗前模型(0.57)和早期治疗模型(0.78)。
- 融合模型预测pCR的AUC在训练集和测试集均为0.91,较Diameter%模型分别提高35.56%和14.19%(P=0和0.039)。
- 列线图显示早期治疗影像组学的Radscore权重最大,临床决策曲线显示融合模型总体临床获益最高。
核心结论
- 影像组学,尤其是变化影像组学和早期治疗影像组学,可能是早期无创预测新辅助治疗结局的潜在生物标志物;由有意义的临床病理指标联合影像组学构建的融合模型可有效预测新辅助治疗反应。
研究设计与样本
- 回顾性分析142例在本机构接受新辅助治疗前及两周期后DCE-MRI的原发浸润性乳腺癌患者的临床和影像数据,按7:3随机分为训练组和测试组,以新辅助治疗后手术病理为参考标准分为病理完全缓解组和非病理完全缓解组。
诊断标准与关键数值
- 测试集中变化影像组学模型AUC为0.87,治疗前影像组学模型AUC为0.57,早期治疗影像组学模型AUC为0.78,Diameter%模型AUC为0.83;融合模型预测pCR的AUC在训练集和测试集均为0.91。
临床应用与阅片要点
- 列线图显示早期治疗影像组学的Radscore权重最大;临床决策曲线显示融合模型总体临床获益最高。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: To compare the value of radiomics and diameter% based on pre- and early-treatment dynamic enhanced MR (DCE-MRI) of the breast in predicting response to neoadjuvant therapy (NAT) in breast cancer and to construct a tool for early noninvasive prediction of NAT outcomes.
MATERIALS AND METHODS: Retrospective analysis of clinical and imaging data of 142 patients with primary invasive breast cancer who underwent DCE-MRI before and after two cycles of NAT at our institution. Enroled patients were randomly assigned in a 7:3 ratio to the training group and the test group. Patients were divided into pathological complete response (pCR) and non-pathological complete response groups based on surgical pathology findings after NAT. The maximum diameter relative regression values (Diameter%) before and after treatment were calculated and the conventional imaging Diameter% model was constructed. Based on pre- and early-NAT DCE-MRI, the optimal features of pre-NAT, early-NAT, and delta radiomics were screened using redundancy analysis, least absolute shrinkage, and selection operator methods to construct the corresponding radiomics model and calculate the Radscores. Indicators that were statistically significant in the univariate analysis of clinical data were further screened by stepwise regression and combined with Radscores to construct the fusion model. All models were evaluated and compared.
RESULTS: In the test set, the area under the curve (AUC) of the delta radiomics model (0.87) was higher than that of the pre-NAT, early-NAT radiomics models (0.57, 0.78) and the Diameter% model (0.83). The fusion model had the best efficacy in predicting pCR after NAT, with AUCs of 0.91 in the training and test sets. And its nomogram plot showed that Radscore of early-NAT radiomics had the greatest weight. In the test set, the fusion model and Delta radiomics model improved the efficacy of predicting pCR by 35.56% and 14.19%, respectively, compared to the Diameter% model (P = 0 and .039). Clinical decision curves showed the highest overall clinical benefit for the fusion model.
CONCLUSION: Radiomics, especially delta and early-NAT radiomics, may be potential biomarkers for early noninvasive prediction of NAT outcomes. And a fusion model constructed from meaningful clinicopathological indicators combined with radiomics can effectively predict NAT response.
引用
- Zeng, Xiong, Liu, et al. Radiomics Based on DCE-MRI for Predicting Response to Neoadjuvant Therapy in Breast Cancer. Acad Radiol. 2023. PMID: 37169624. doi:10.1016/j.acra.2023.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。